53332-67-5 Usage
Uses
Used in Pharmaceutical Research:
(1-METHYL-1H-IMIDAZOL-2-YL)METHANAMINE DIHYDROCHLORIDE is used as a research compound for the development of new drugs, particularly for the treatment of infectious diseases. Its antiviral and antimicrobial properties make it a promising candidate for combating various pathogens.
Used in Neurological Disorder Treatment:
(1-METHYL-1H-IMIDAZOL-2-YL)METHANAMINE DIHYDROCHLORIDE is used as a potential therapeutic agent for neurological disorders such as epilepsy and schizophrenia. Its effects on the nervous system are being studied to explore its potential benefits in managing these conditions.
Used in Organic Synthesis:
(1-METHYL-1H-IMIDAZOL-2-YL)METHANAMINE DIHYDROCHLORIDE is used as a reagent in organic synthesis, where its unique chemical properties can be utilized to create new compounds or modify existing ones.
It is important to handle (1-METHYL-1H-IMIDAZOL-2-YL)METHANAMINE DIHYDROCHLORIDE with caution, as it may pose health hazards if not used properly. The dihydrochloride salt form of (1-METHYL-1H-IMIDAZOL-2-YL)METHANAMINE DIHYDROCHLORIDE is commonly used to improve its solubility and stability for laboratory and industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 53332-67-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,3,3 and 2 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 53332-67:
(7*5)+(6*3)+(5*3)+(4*3)+(3*2)+(2*6)+(1*7)=105
105 % 10 = 5
So 53332-67-5 is a valid CAS Registry Number.
InChI:InChI=1/C5H9N3.2ClH/c1-8-3-2-7-5(8)4-6;;/h2-3H,4,6H2,1H3;2*1H
53332-67-5Relevant academic research and scientific papers
2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES
-
Page 74, (2010/02/07)
Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
